Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.
作者信息
Smeenk Michiel M, van der Noort Vincent, Hendrikx Jeroen J M A, Abedian Kalkhoran Hanieh, Smit Egbert F, Theelen Willemijn S M E
机构信息
Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands.
Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
出版信息
J Immunother Cancer. 2025 Jul 22;13(7):e012594. doi: 10.1136/jitc-2025-012594.
Abstract
摘要
相似文献
1
Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.对王关于“帕博利珠单抗混合给药在晚期非小细胞肺癌中不劣于固定剂量给药——一项真实世界、回顾性双中心队列研究”的通信的回应。
J Immunother Cancer. 2025 Jul 22;13(7):e012594. doi: 10.1136/jitc-2025-012594.
2
Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Smeenk .关于Smeenk的《帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究》的通信
J Immunother Cancer. 2025 Jul 22;13(7):e011895. doi: 10.1136/jitc-2025-011895.
3
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.对朱的《帕博利珠单抗混合给药在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究》评论的回应
J Immunother Cancer. 2025 Jul 22;13(7):e012095. doi: 10.1136/jitc-2025-012095.
4
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010065. doi: 10.1136/jitc-2024-010065.
5
Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'.对“帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究”的评论
J Immunother Cancer. 2025 Mar 6;13(3):e011845. doi: 10.1136/jitc-2025-011845.
6
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors.帕博利珠单抗单药治疗高程序性死亡配体1表达的晚期或转移性非小细胞肺癌的成本效益取决于长期存活者。
Clin Drug Investig. 2025 Jul 9. doi: 10.1007/s40261-025-01456-5.
7
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
8
Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.谈谈性别差异：帕博利珠单抗治疗非小细胞肺癌的真实世界队列中女性和男性的生存率
Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35445.
9
IgE-mediated anaphylaxis induced by pembrolizumab.帕博利珠单抗诱导的IgE介导的过敏反应。
Immunotherapy. 2025 Jun;17(9):625-629. doi: 10.1080/1750743X.2025.2527589. Epub 2025 Jul 8.
10
ANV600 is a novel PD-1 targeted IL-2Rβγ agonist that selectively expands tumor antigen-specific T cells and potentiates PD-1 checkpoint inhibitor therapy.ANV600是一种新型的靶向程序性死亡受体1（PD-1）的白细胞介素-2受体βγ激动剂，可选择性扩增肿瘤抗原特异性T细胞，并增强程序性死亡受体1（PD-1）检查点抑制剂疗法的效果。
J Immunother Cancer. 2025 Jul 15;13(7):e011905. doi: 10.1136/jitc-2025-011905.
本文引用的文献
1
Response to: Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Zhu.对朱的《帕博利珠单抗混合给药在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究》评论的回应
J Immunother Cancer. 2025 Jul 22;13(7):e012095. doi: 10.1136/jitc-2025-012095.
2
Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study' by Smeenk .关于Smeenk的《帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究》的通信
J Immunother Cancer. 2025 Jul 22;13(7):e011895. doi: 10.1136/jitc-2025-011895.
3
Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'.对“帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究”的评论
J Immunother Cancer. 2025 Mar 6;13(3):e011845. doi: 10.1136/jitc-2025-011845.
4
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study.帕博利珠单抗混合给药方案在晚期非小细胞肺癌中不劣于固定剂量给药：一项真实世界、回顾性双中心队列研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010065. doi: 10.1136/jitc-2024-010065.
5
Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90.化疗免疫治疗与免疫治疗用于 PD-L1 表达≥50%或≥90%的晚期非小细胞肺癌一线治疗
Clin Lung Cancer. 2023 May;24(3):235-243. doi: 10.1016/j.cllc.2023.02.007. Epub 2023 Mar 1.
6
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。
J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.
7
Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.帕博利珠单抗联合化疗治疗鳞状非小细胞肺癌：III 期 KEYNOTE-407 研究的 5 年更新结果。
J Clin Oncol. 2023 Apr 10;41(11):1999-2006. doi: 10.1200/JCO.22.01990. Epub 2023 Feb 3.
8
Oligoprogression in non-small cell lung cancer: a narrative review.非小细胞肺癌中的寡进展：一篇叙述性综述
J Thorac Dis. 2022 Dec;14(12):4998-5011. doi: 10.21037/jtd-22-536.
9
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis.免疫检查点抑制剂单药与免疫检查点抑制剂联合化疗治疗高 PD-L1 表达 NSCLC 患者：一项网络荟萃分析。
Br J Cancer. 2022 Sep;127(5):948-956. doi: 10.1038/s41416-022-01832-4. Epub 2022 May 31.
10
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.在程序性死亡受体配体1（PD-L1）表达≥50%的非小细胞肺癌患者中，一线使用帕博利珠单抗联合或不联合铂类双药化疗。
Future Oncol. 2021 Aug;17(23):3007-3016. doi: 10.2217/fon-2020-1202. Epub 2021 Jun 22.
Zotero 插件